AbbVie announced that MAVIRET® (glecaprevir/pibrentasvir tablets) is now listed on the Newfoundland and Labrador Formulary. MAVIRET is a once-daily ribavirin-free treatment for adults and adolescent patients 12 to 18 years of age with chronic hepatitis C virus (HCV) infection across all major HCV genotypes (GT1-6). It is an 8-week, pan-genotypic treatment for patients without cirrhosis and who are new to treatment. MAVIRET is listed on the Newfoundland and Labrador Formulary for treatment-naive or treatment-experienced adult patients with chronic hepatitis C genotype 1,2,3,4,5 or 6 infection. MAVIRET's efficacy and safety were evaluated in nine phase II-III clinical trials, in over 2300 patients with genotype 1, 2, 3, 4, 5 or 6 HCV infection and with compensated liver disease (with or without cirrhosis).